https://www.selleckchem.com/pr....oducts/trastuzumab-d
3) After RPE tear develops, anti-VEGF treatment should be continued in patients with active disease (as indicated by presence of intraretinal or subretinal fluid), although cessation of therapy should be considered in eyes with multilobular tears. Although evidence to support the assumption that anti-VEGF treatment contributes to development of RPE tear is not definitive, some data suggest this link. Although evidence to support the assumption that anti-VEGF treatment contributes to development of RPE tear is not definiti
Like
Comment
Share
